{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:39:48Z","timestamp":1793785188320,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sun Pharmaceutical Industries, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s13555-021-00588-8","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T16:03:12Z","timestamp":1630944192000},"page":"1839-1849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-2820","authenticated-orcid":false,"given":"Ralf","family":"Gutzmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dr\u00e9no","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Guminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Arntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Squittieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenal","family":"Kheterpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"issue":"9","key":"588_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1001\/jamadermatol.2015.1188","volume":"151","author":"MM Asgari","year":"2015","unstructured":"Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998\u20132012. JAMA Dermatol. 2015;151(9):976\u201381.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"588_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s13671-014-0069-y","volume":"3","author":"SV Mohan","year":"2014","unstructured":"Mohan SV, Chang AL. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep. 2014;3(1):40\u20135.","journal-title":"Curr Dermatol Rep"},{"issue":"2","key":"588_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5826\/dpc.0702a01","volume":"7","author":"Z Apalla","year":"2017","unstructured":"Apalla Z, Lallas A, Sotiriou E, Lazaridou E, Ioannides D. Epidemiological trends in skin cancer. Dermatol Pract Concept. 2017;7(2):1\u20136.","journal-title":"Dermatol Pract Concept"},{"issue":"3","key":"588_CR4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jaad.2017.10.006","volume":"78","author":"JYS Kim","year":"2018","unstructured":"Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78(3):540\u201359.","journal-title":"J Am Acad Dermatol"},{"key":"588_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2019.06.003","volume":"118","author":"K Peris","year":"2019","unstructured":"Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019;118:10\u201334.","journal-title":"Eur J Cancer"},{"issue":"6","key":"588_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1684\/ejd.2015.2641","volume":"25","author":"JM Amici","year":"2015","unstructured":"Amici JM, Battistella M, Beylot-Barry M, et al. Defining and recognising locally advanced basal cell carcinoma. Eur J Dermatol. 2015;25(6):586\u201394.","journal-title":"Eur J Dermatol"},{"issue":"5","key":"588_CR7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaad.2014.05.020","volume":"71","author":"MS Ally","year":"2014","unstructured":"Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014;71(5):904-11.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"588_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","volume":"70","author":"AL Chang","year":"2014","unstructured":"Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"588_CR9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrc2503","volume":"8","author":"EH Epstein","year":"2008","unstructured":"Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743\u201354.","journal-title":"Nat Rev Cancer"},{"key":"588_CR10","unstructured":"Odomzo (sonidegib capsules). Full prescribing information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ, USA, 2017."},{"key":"588_CR11","unstructured":"Erivedge (vismodegib capsules). Full prescribing information. Genentech, San Francisco, CA, USA, 2019."},{"key":"588_CR12","unstructured":"European Medicines Agency. Summary of product characteristics, WC500188762, 2015."},{"key":"588_CR13","unstructured":"Australian Government Department of Health, ARTG 292262, 2015."},{"key":"588_CR14","unstructured":"Swissmedic, Authorization Number 65065, 2015."},{"key":"588_CR15","unstructured":"DHPC \u2013 Erivedge\u00ae (Vismodegib). Swissmedic 2016."},{"key":"588_CR16","unstructured":"European Medicines Agency. Summary of product characteristics, EMEA\/H\/C\/002602."},{"issue":"6","key":"588_CR17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/bjd.18552","volume":"182","author":"R Dummer","year":"2020","unstructured":"Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369\u201378.","journal-title":"Br J Dermatol"},{"issue":"6","key":"588_CR18","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","volume":"16","author":"MR Migden","year":"2015","unstructured":"Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716\u201328.","journal-title":"Lancet Oncol"},{"key":"588_CR19","unstructured":"Data on file. Sonidegib adverse events 21-month follow up. Provided by Sun Pharmaceuticals Industries Ltd, 2018."},{"key":"588_CR20","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. United States National Cancer Institute. 2010. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"key":"588_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/9781444311723","volume-title":"A concise guide to clinical trials","author":"A Hackshaw","year":"2009","unstructured":"Hackshaw A. A concise guide to clinical trials. Chichester: BMJ Books; 2009. p. 224."},{"key":"588_CR22","doi-asserted-by":"publisher","first-page":"d2304","DOI":"10.1136\/bmj.d2304","volume":"343","author":"DG Altman","year":"2011","unstructured":"Altman DG, Bland JM. How to obtain the P value from a confidence interval. BMJ. 2011;343:d2304.","journal-title":"BMJ"},{"key":"588_CR23","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1111\/jdv.16230","volume":"34","author":"R Dummer","year":"2020","unstructured":"Dummer R, Ascierto P, Basset-Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020;34:1944\u201356.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"588_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","volume":"17","author":"A Sekulic","year":"2017","unstructured":"Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.","journal-title":"BMC Cancer"},{"issue":"23","key":"588_CR25","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMe1202170","volume":"366","author":"JT Lear","year":"2012","unstructured":"Lear JT. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med. 2012;366(23):2225\u20136.","journal-title":"N Engl J Med"},{"key":"588_CR26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","volume":"86","author":"N Basset-S\u00e9guin","year":"2017","unstructured":"Basset-S\u00e9guin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334\u201348.","journal-title":"Eur J Cancer"},{"issue":"3","key":"588_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","volume":"18","author":"B Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404\u201312.","journal-title":"Lancet Oncol"},{"issue":"1","key":"588_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00280-014-2468-y","volume":"74","author":"M Zollinger","year":"2014","unstructured":"Zollinger M, Lozac\u2019h F, Hurh E, Emotte C, Bauly H, Swart P. Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol. 2014;74(1):63\u201375.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"588_CR29","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/1078-0432.CCR-10-2736","volume":"17","author":"RA Graham","year":"2011","unstructured":"Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res. 2011;17(8):2512\u201320.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"588_CR30","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00280-016-2982-1","volume":"77","author":"V Goel","year":"2016","unstructured":"Goel V, Hurh E, Stein A, et al. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77(4):745\u201355.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00588-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00588-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00588-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T18:03:29Z","timestamp":1633025009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00588-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00588-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"27 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}